FIGURE 1: Blockade of inhibitory DAMP convert gemcitabine into an ICD-inducer that primes a durable CD8⁺ T cell response. (a) Gemcitabine as a single chemotherapy induces tolerogenicity. (b) When gemcitabine is complemented with iDAMP blockade, an antitumoral immune response is elicited. (c) iDAMP blockade is expected to augment chemotherapy and immune checkpoint blockade therapies.